Selvamuthu Poongulali

High Frequency of Clinically Significant Mutations after First‐Line Generic Highly Active Antiretroviral Therapy Failure: Implications for Second‐Line Options in Resource‐Limited Settings

N. Kumarasamy, Vidya Madhavan, Kartik K. Venkatesh et al. · Clinical Infectious Diseases · 2009 · 65 citations · Full text

Drug Resistance Mutations, Treatment And Prevention, Human Retrovirus +13

A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults

Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, Anne Bollaerts et al. · Medicine · 2016 · 60 citations · Full text

Hiv-positive Indian Adults, Immunodeficiencies, Tuberculosis Prevention +18

Spectrum of Adverse Events After Generic HAART in Southern Indian HIV-Infected Patients

N. Kumarasamy, Kartik K. Venkatesh, Anitha J. Cecelia et al. · AIDS Patient Care and STDs · 2008 · 57 citations

‘The phone reminder is important, but will others get to know about my illness?’ Patient perceptions of an mHealth antiretroviral treatment support intervention in the HIVIND trial in South India

Rashmi Rodrigues, Selvamuthu Poongulali, K. Balaji et al. · BMJ Open · 2015 · 56 citations · Full text

Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults

Nagalingeswaran Kumarasamy, Selvamuthu Poongulali, Faith Esther Beulah et al. · Medicine · 2018 · 46 citations · Full text